An exploratory randomized, double-blind trial of accelerated deep TMS for patients with suicidal thoughts and behaviors
Journal of Affective Disorders · 2026
DOI: 10.1016/j.jad.2025.120705 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Esther Bloemhof-Bris und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lev Hasharon Mental Health Center, Tzur Moshe, Israel. Electronic address: estherbl@lev-hasharon.co.il. Hauptthemen laut MEDLINE: Major Depressive Disorder, Suicidal Ideation, Transcranial Magnetic Stimulation. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Suicidality is a leading cause of death in major depressive disorder (MDD), yet actively suicidal patients are rarely included in neuromodulation trials. Evidence for deep transcranial magnetic stimulation (dTMS) in this group is limited. OBJECTIVE: Assess the safety and efficacy of accelerated H1/H7 dTMS in MDD inpatients with active suicidality. METHODS: In a double-blind, randomized, sham-controlled pilot trial, 39 inpatients received ten days of accelerated dTMS (three daily intermittent theta-burst sessions) using H1, H7, or sham coils. Columbia Suicide Severity Rating Scale (C-SSRS), Quick Inventory of Depressive Symptomatology (QIDS), and Montgomery-Åsberg Depression Rating Scale (MADRS) were completed at baseline, day 5, and day 10. RESULTS: Of the 39 enrolled patients, 31 completed at least nine treatment days and were included in the efficacy analysis. Adverse events were mild and transient; two patients discontinued treatment. Active arms (H1/H7) produced greater reductions in QIDS than sham. C-SSRS suicidal ideation/behavior category declined over time in all groups, but only the active cohort showed a lower suicidal ideation intensity by day 10. CONCLUSIONS: Accelerated dTMS with either coil appears to be safe, tolerable, and logistically feasible for acutely suicidal MDD inpatients. Active stimulation yielded a clinically meaningful antidepressant response and a promising signal for faster resolution of suicidality. Those preliminary findings encourage inclusion of suicidal individuals in neuromodulation studies and support dTMS as a potential rapid intervention during psychiatric crises; confirmation in larger multicenter samples is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lev Hasharon Mental Health Center, Tzur Moshe, Israel. Electronic address: estherbl@lev-hasharon.co.il.
- The Lior Tsfaty Center for Suicide and Mental Pain Studies, University of Haifa, Haifa, Israel.
- Lev Hasharon Mental Health Center, Tzur Moshe, Israel.
- Lev Hasharon Mental Health Center, Tzur Moshe, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Zitieren
APA
Bloemhof-Bris, E., Levi-Belz, Y., Tamary Guterman, A., Wexler, G., Noam, S., Cohen, S., & Feffer, K. (2026). An exploratory randomized, double-blind trial of accelerated deep TMS for patients with suicidal thoughts and behaviors. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120705
Vancouver
Bloemhof-Bris E, Levi-Belz Y, Tamary Guterman A, Wexler G, Noam S, Cohen S, et al. An exploratory randomized, double-blind trial of accelerated deep TMS for patients with suicidal thoughts and behaviors. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120705
BibTeX
@article{BloemhofBris2026,
author = {Bloemhof-Bris, Esther and Levi-Belz, Yossi and Tamary Guterman, Adi and Wexler, Gay and Noam, Sigalit and Cohen, Shiri and Feffer, Kfir},
title = {An exploratory randomized, double-blind trial of accelerated deep TMS for patients with suicidal thoughts and behaviors},
journal = {Journal of Affective Disorders},
year = {2026},
doi = {10.1016/j.jad.2025.120705}
}
EUVIMED